Lucentis Effective for Proliferative Diabetic Retinopathy (VIDEO)
Caption
NIH-funded clinical trial marks first major advance in therapy in 40 years.
A clinical trial funded by the National Institutes of Health has found that the drug ranibizumab (Lucentis) is highly effective in treating proliferative diabetic retinopathy. The trial, conducted by the Diabetic Retinopathy Clinical Research Network (DRCR.net) compared Lucentis with a type of laser therapy called panretinal or scatter photocoagulation, which has remained the gold standard for proliferative diabetic retinopathy since the mid-1970s.
Credit
National Eye Institute
Usage Restrictions
Courtesy of the National Eye Institute
License
Licensed content